Johnson & Johnson (NYSE:JNJ) Shares Down 1.3% - Here's What Happened

Key Points

• Johnson & Johnson shares fell 1.3% to about $264.13 on Friday, with trading volume 34% below its average.
• The company received positive developments, including U.K. approval for its oral psoriasis treatment and encouraging real-world data for its atrial-fibrillation MedTech platforms. However, a reported collapse of a potential orthopedics combination and concerns about valuation, earnings estimates and MedTech execution weighed on sentiment.
• Analyst opinion remains broadly favorable, with a “Moderate Buy” consensus and an average price target of $275.92. J&J also beat quarterly earnings estimates, reported 5.9% year-over-year revenue growth and declared a $1.34 quarterly dividend, yielding about 2.0%.

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price dropped 1.3% on Friday. The company traded as low as $262.40 and last traded at $264.1310. 5,307,717 shares traded hands during trading, a decline of 34% from the average session volume of 7,985,994 shares. The stock had previously closed at $267.61.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J's oral psoriasis pill
• Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
• Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
• Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
• Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
• Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Freedom Capital raised shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. The Goldman Sachs Group restated a "buy" rating and set a $282.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a research note on Friday, October 16th. Evercore set a $300.00 price objective on shares of Johnson & Johnson in a report on Tuesday. Finally, Erste Group Bank downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $275.92.

Johnson & Johnson Stock Down 1.3%

The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $636.53 billion, a PE ratio of 40.02, a P/E/G ratio of 2.55 and a beta of 0.21. The stock's fifty day simple moving average is $265.57 and its 200-day simple moving average is $250.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the prior year, the company posted $2.80 earnings per share. The firm's revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,515 shares of company stock valued at $17,271,766 in the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds have recently made changes to their positions in the business. Outlook Capital Management LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $28,000. Matrix Trust Co increased its stake in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $43,000. Polaris Financial Partners bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $56,000. Finally, Bullseye Investment Management LLC purchased a new position in Johnson & Johnson in the second quarter valued at approximately $63,000. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.